Tumour angiogenesis is a vital process in the pathology of tumour development and metastasis. Targeting markers of tumour endothelium provide a means of targeted destruction of a tumours oxygen and nutrient supply via destruction of tumour vasculature, which in turn ultimately leads to beneficial consequences to patients. Although current anti-angiogenic and vascular targeting strategies help patients, more potently in combination with chemo therapy, there is still a need for more tumour endothelial marker discoveries as current treatments have cardiovascular and other side effects. For the first time, the analyses of in-vivo biotinylation of an embryonic system is performed to obtain putative vascular targets. Also for the first time, deep sequencing is applied to freshly isolated tumour and normal endothelial cells from lung, colon and bladder tissues for the identification of pan-vascular-targets. Integration of the proteomic, deep sequencing, public cDNA libraries and microarrays, delivers 5,892 putative vascular targets to the science community. These analyses identify Endothelial Specific Molecule 1 as a pan vascular target and lysyl oxidase-like 2 as putative novel vascular target. It is envisioned vascular targets and angiogenesis genes in this data will destroy or inhibit tumour vessel growth without the side effects manifest with current clinical regimens.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:563984 |
| Date | January 2013 |
| Creators | Herbert, John Matthew Jeff |
| Publisher | University of Birmingham |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
| Source | http://etheses.bham.ac.uk//id/eprint/3803/ |
Page generated in 0.0015 seconds